Latest news for Proteonomix (OTC:PROT) Stock

Proteonomix Inc develops pre-clinical-stage therapeutic agents and treatments for diabetes, heart, and lung diseases. The company focuses on developing therapeutics based upon the use of human cells and their derivative.

Long Ideas

News

Short Ideas

Small Cap

Global

After-Hours Center

Movers

Trading Ideas

AEZS

GPRC

GRPC

PROT

Benzinga&#39;s Microcap Movers for Monday August 14, 2012

Tech

INSM

SCHS

Benzinga&#39;s Microcap Movers for Friday January 20, 2012

Proteonomix Inc

PROTEO INC by Proteo, Inc.

PROTIDE PHARMS INC by Protide Pharmaceuticals, Inc.

PROTEK CAPITAL INC by ProTek Capital, Inc.

ProTek Capital Inc

PROTEXT MOBILITY INC by ProText Mobility, Inc.

ProText Mobility Inc

Protagenic Therapeutics Inc

Protagenic Therapeutics, Inc. - Common Stock

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics Inc

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics Inc

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics Inc

PROTEAK UNO SAPIB DE CV by Proteak Uno Sapib De Cv

Proteak Uno SAPI B de CV

PROTECT PHARMS CORP by Protect Pharmaceutical Corp

Protect Pharmaceutical Corp

PROTECTOR FORSIKRING ORD by Protector Forsikring ASA

Protector Forsikring ASA

PROTECTOR FRKRNG UNSP/ADR by Protector Forsikring ASA

PROTEIN REACTOR COMBINED by Protein Reactor Combined Fuels Inc

Protein Reactor Combined Fuels Inc

PROTEOME SCIENCES PLC by Proteome Sciences PLC

Proteome Sciences PLC

PROTEOMICS INTL LAB LTD by PROTEOMICS INTL LABORATORIES LTD.

Proteomics International Laboratories Ltd

Proterra Inc

Prothena Corporation plc - Ordinary Shares

Prothena Corp PLC

Proto Corp

Proto Labs Inc

PROTO SCRIPT PHARMA by Proto Script Pharmaceutical Corp.

Proto Script Pharmaceutical Corp

ProtoKinetix Inc

ProtoSource Corp

Protocall Technologies Inc

PROTOCALL TECHS INC by Protocall Technologies, Inc.

Proton

Below are highlights from Benzinga's daily coverage of small cap and microcap securities making big moves:

Proteonomix

Shares of Proteonomix (<a class="ticker" href="/stock/prot#">PROT</a>), the Mountainside, NJ biotechnology company, rose 155% Monday on 3 times average volume.

Proteonomix announced Tuesday that the U.S. Food and Drug Administration has granted permission to the Company to initiate a Phase 1 clinical trial with its mobilization technology UMK-121. The Proteonomix-sponsored trial will evaluate UMK-121 in patients with end-stage liver disease.

“Permission by the FDA marks an important milestone in our plans to initiate a Company-sponsored clinical trial with UMK-121, following years of research and investment to advance development of this drug candidate,” said Proteonomix Chief Technology Officer Steven Byle. “We hope and anticipate that this trial will demonstrate the potential of UMK-121 to mobilize stem cells in order to improve liver function in patients with ESLD. We consider ourselves fortunate to be involved with a development-stage therapy that could improve the life expectancy for this class of terminally ill 
patients awaiting liver transplants.”

Proteonomix closed at $4.11 on Monday.

Guanwei Recycling

Shares of Guanwei Recycling (NASDAQ: <a class="ticker" href="/stock/gprc#NASDAQ">GPRC</a>), the China-based manufacturer and distributor of low density polyethylene, rose 38.10% Monday on 13 times average volume.

Guanwei Recycling reported Tuesday that revenues in its second quarter ended June 30, 2012 increased 18.6% to $18,694,938, including $1,773,129 from the resale of raw materials, compared with revenues of $15,757,662 in the same quarter last year. The Company also reported an increase of 3.41% in the selling prices of its manufactured recycled LDPE year over year. However, this increase was not sufficient to offset increased raw material, labor and overhead costs in the period. The resulting lower profit margins contributed to an 8.41% year over year decline in net income to 
$3,163,030, or $0.15 per share, compared with $3,453,360, or $0.17 per share, in the 2011 second quarter.

Guanwei Recycling closed at $0.87 on Monday.

Aeterna Zentaris

Shares of Aeterna Zentaris (NASDAQ: <a class="ticker" href="/stock/aezs#NASDAQ">AEZS</a>), the Canada-based biopharmaceutical company, rose 33.33% Monday on almost 3 times average volume.

Aeterna Zentaris reported Tuesday financial and operating results as at and for the second quarter ended June 30, 2012.

Revenues were $7.5 million for the quarter ended June 30, 2012, compared to $6.5 million for the same quarter in 2011. This increase is largely attributable to comparative higher deliveries of Cetrotide to certain customers and to higher research and development services provided, partly offset by the relative weakening of the euro against the US dollar.

Net income amounted to $4.5 million, or $0.04 per basic and diluted share, for the quarter ended June 30, 2012, compared to a net loss of $10.6 million, or $0.12 per basic and diluted share, for the same quarter in 2011. This significant decrease in net loss is mainly attributable to higher net finance income.

Aeterna Zentaris closed at $0.51 on Monday.

The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment.

Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.

Benzinga's Microcap Movers for Monday August 14, 2012

Analyst Color

Price Target

Initiation

Analyst Ratings

Haring Morgan Joseph Initiates Proteonomix with Buy and $8 PT

Rumors

Proteonomix Rises 25%

Below are highlights from Benzinga's daily coverage of microcap securities making big moves:

Proteonomix

Shares of Proteonomix (PROT), the Mountainside, NJ biotechnology company, rose 31% Friday on almost 9 times the average daily volume.

Proteonomix was the subject of chat room and twitter discussion on Friday. There was no news associated with the price move. The company is developing treatments for a wide range of diseases using stem cells. 

Proteonomix closed at $2.39 Friday.

Insmed

Shares of Insmed, (NASDAQ: <a class="ticker" href="/stock/insm#NASDAQ">INSM</a>), the Monmouth Junction, NJ biopharmaceutical company, rose 31% Friday on 26 times the average daily volume.

Insmed announced Friday that the U.S. Food and Drug Administration had lifted the clinical hold previously placed on ARIKACE in patients with non-tuberculous mycobacteria lung disease. Insmed continues to engage in discussions with FDA regarding the clinical hold placed on ARIKACE in Cystic Fibrosis patients with Pseudomonas lung infections.

The clinical holds placed on the ARIKACE programs in NTM and CF were based on an initial review by FDA of the results reported by Insmed of a long-term rat inhalation carcinogenicity study of ARIKACE.

Insmed Interactive closed at $5.01 Friday.

School Specialty

Shares of School Specialty (NASDAQ: <a class="ticker" href="/stock/schs#NASDAQ">SCHS</a>), the Greenville, WI education company, rose 20% Friday on 4.5 times the average daily volume.

School Specialty announced Friday its 2012 expanded offering of classroom technology solutions. Meeting customers' continuously evolving technology needs, this comprehensive product assortment offers tools necessary to prepare students with 21st Century learning skills and augment traditional educational methods.

School Specialty closed at $2.93 Friday.

Benzinga's Microcap Movers for Friday January 20, 2012

Proteonomix

Below are highlights from Benzinga's daily coverage of small cap and microcap securities making big moves:

Proteonomix

Shares of Proteonomix (<a class="ticker" href="/stock/prot#">PROT</a>), the Mountainside, NJ biotechnology company, rose 155% Monday on 3 times average volume.

Proteonomix announced Tuesday that the U.S. Food and Drug Administration has granted permission to the Company to initiate a Phase 1 clinical trial with its mobilization technology UMK-121. The Proteonomix-sponsored trial will evaluate UMK-121 in patients with end-stage liver disease.

“Permission by the FDA marks an important milestone in our plans to initiate a Company-sponsored clinical trial with UMK-121, following years of research and investment to advance development of this drug candidate,” said Proteonomix Chief Technology Officer Steven Byle. “We hope and anticipate that this trial will demonstrate the potential of UMK-121 to mobilize stem cells in order to improve liver function in patients with ESLD. We consider ourselves fortunate to be involved with a development-stage therapy that could improve the life expectancy for this class of terminally ill 
patients awaiting liver transplants.”

Proteonomix closed at $4.11 on Monday.


Guanwei Recycling

Shares of Guanwei Recycling (NASDAQ: <a class="ticker" href="/stock/gprc#NASDAQ">GPRC</a>), the China-based manufacturer and distributor of low density polyethylene, rose 38.10% Monday on 13 times average volume.

Guanwei Recycling reported Tuesday that revenues in its second quarter ended June 30, 2012 increased 18.6% to $18,694,938, including $1,773,129 from the resale of raw materials, compared with revenues of $15,757,662 in the same quarter last year. The Company also reported an increase of 3.41% in the selling prices of its manufactured recycled LDPE year over year. However, this increase was not sufficient to offset increased raw material, labor and overhead costs in the period. The resulting lower profit margins contributed to an 8.41% year over year decline in net income to 
$3,163,030, or $0.15 per share, compared with $3,453,360, or $0.17 per share, in the 2011 second quarter.

Guanwei Recycling closed at $0.87 on Monday.


Aeterna Zentaris

Shares of Aeterna Zentaris (NASDAQ: <a class="ticker" href="/stock/aezs#NASDAQ">AEZS</a>), the Canada-based biopharmaceutical company, rose 33.33% Monday on almost 3 times average volume.

Aeterna Zentaris reported Tuesday financial and operating results as at and for the second quarter ended June 30, 2012.

Revenues were $7.5 million for the quarter ended June 30, 2012, compared to $6.5 million for the same quarter in 2011. This increase is largely attributable to comparative higher deliveries of Cetrotide to certain customers and to higher research and development services provided, partly offset by the relative weakening of the euro against the US dollar.

Net income amounted to $4.5 million, or $0.04 per basic and diluted share, for the quarter ended June 30, 2012, compared to a net loss of $10.6 million, or $0.12 per basic and diluted share, for the same quarter in 2011. This significant decrease in net loss is mainly attributable to higher net finance income.

Aeterna Zentaris closed at $0.51 on Monday.


The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment.

Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.

Below are highlights from Benzinga's daily coverage of microcap securities making big moves:

Proteonomix

Shares of Proteonomix (PROT), the Mountainside, NJ biotechnology company, rose 31% Friday on almost 9 times the average daily volume.

Proteonomix was the subject of chat room and twitter discussion on Friday. There was no news associated with the price move. The company is developing treatments for a wide range of diseases using stem cells. 

Proteonomix closed at $2.39 Friday.


Insmed

Shares of Insmed, (NASDAQ: <a class="ticker" href="/stock/insm#NASDAQ">INSM</a>), the Monmouth Junction, NJ biopharmaceutical company, rose 31% Friday on 26 times the average daily volume.

Insmed announced Friday that the U.S. Food and Drug Administration had lifted the clinical hold previously placed on ARIKACE in patients with non-tuberculous mycobacteria lung disease. Insmed continues to engage in discussions with FDA regarding the clinical hold placed on ARIKACE in Cystic Fibrosis patients with Pseudomonas lung infections.

The clinical holds placed on the ARIKACE programs in NTM and CF were based on an initial review by FDA of the results reported by Insmed of a long-term rat inhalation carcinogenicity study of ARIKACE.

Insmed Interactive closed at $5.01 Friday.


School Specialty

Shares of School Specialty (NASDAQ: <a class="ticker" href="/stock/schs#NASDAQ">SCHS</a>), the Greenville, WI education company, rose 20% Friday on 4.5 times the average daily volume.

School Specialty announced Friday its 2012 expanded offering of classroom technology solutions. Meeting customers' continuously evolving technology needs, this comprehensive product assortment offers tools necessary to prepare students with 21st Century learning skills and augment traditional educational methods.

School Specialty closed at $2.93 Friday.

Comments

Proteonomix

News

Latest news for Proteonomix (OTC:PROT) Stock

Tuesday, August 14, 2012

Thursday, March 01, 2012

Monday, January 23, 2012

Sunday, January 22, 2012

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga